14.19
+0.54(+3.96%)
Currency In USD
| Previous Close | 13.65 |
| Open | 13.62 |
| Day High | 14.42 |
| Day Low | 13.61 |
| 52-Week High | 14.42 |
| 52-Week Low | 3.91 |
| Volume | 1.15M |
| Average Volume | 735,666 |
| Market Cap | 978.08M |
| PE | -5.28 |
| EPS | -2.69 |
| Moving Average 50 Days | 10.84 |
| Moving Average 200 Days | 8.08 |
| Change | 0.54 |
If you invested $1000 in EyePoint Pharmaceuticals, Inc. (EYPT) 10 years ago, it would be worth $378.4 as of September 10, 2025 at a share price of $14.19. Whereas If you bought $1000 worth of EyePoint Pharmaceuticals, Inc. (EYPT) shares 5 years ago, it would be worth $2,782.35 as of September 10, 2025 at a share price of $14.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire Inc.
Aug 06, 2025 11:30 AM GMT
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today a
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire Inc.
Jul 30, 2025 11:00 AM GMT
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today a
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
GlobeNewswire Inc.
Jul 29, 2025 11:00 AM GMT
– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – Over 800 patients enrolled across the LUGANO an